Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

This article summarizes current health news, covering topics like potential bone loss from thyroid medication, dementia risks from wildfire smoke, and updates on pharmaceutical pricing policies. It ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Shares of Amgen Inc. ($AMGN) edged down 0.3% in premarket trading Wednesday, on course to extend a losing streak to a third ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Amgen's MariTide ... across obesity and related conditions. Cantor said the 20% weight loss is "actually pretty decent" especially if it could continue to fall beyond 52 weeks. "But there are still a ...